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therapeutic nanovectors there are, how-
ever, a number of issues that cause con-
tention: (1) the use of harmful substances 
in the fabrication process, (2) elucidating 
the exact physicochemical nature of the 
resulting nanostructure, and (3) iden-
tifying the key physical features that 
determine biochemical performance.[1–6] 
Addressing these issues is especially per-
tinent because so many nanomedical 
formulations fail to reach the clinic due 
to unforeseen complications.[7] For this 
reason, structures generated by the self-
assembly of amphiphilic block copolymers 
have received much attention due to their 
excellent versatility and physical proper-
ties.[8–14] In particular, the implementation 
of biodegradable copolymers comprising 
polyesters and polycarbonates, in combi-
nation with poly(ethylene glycol) (PEG), 
has received increasing attention due to 
their biocompatibility.[15–18] However, typ-
ical approaches to their synthesis and fab-
rication can be greatly improved, in order 
to decrease reliance upon potentially toxic 
catalysts and organic solvents. Moreover, 
it is critically important to have an accu-
rate picture of the size and shape of the drug nanovectors so 
that performance in vitro and in vivo can be concisely related to 
these parameters.[19–27]
In particular, the ubiquity of harmful solvents and complex 
methodologies in the fabrication of drug-loaded delivery vectors 
The stabilization and transport of low-solubility drugs, by encapsulation in 
nanoscopic delivery vectors (nanovectors), is a key paradigm in nanomedicine. 
However, the problems of carrier toxicity, specificity, and producibility create a 
bottleneck in the development of new nanomedical technologies. Copolymeric 
nanoparticles are an excellent platform for nanovector engineering due to their 
structural versatility; however, conventional fabrication processes rely upon 
harmful chemicals that necessitate purification. In engineering a more robust 
(copolymeric) nanovector platform, it is necessary to reconsider the entire 
process from copolymer synthesis through self-assembly and functionalization. 
To this end, a process is developed whereby biodegradable copolymers of 
poly(ethylene glycol)-block-poly(trimethylene carbonate), synthesized via 
organocatalyzed ring-opening polymerization, undergo assembly into highly 
uniform, drug-loaded micelles without the use of harmful solvents or the need 
for purification. The direct hydration methodology, employing oligo(ethylene 
glycol) as a nontoxic dispersant, facilitates rapid preparation of pristine, drug-
loaded nanovectors that require no further processing. This method is robust, 
fast, and scalable. Utilizing parthenolide, an exciting candidate for treatment 
of acute lymphoblastic leukemia (ALL), discrete nanovectors are generated 
that show strikingly low carrier toxicity and high levels of specific therapeutic 
efficacy against primary ALL cells (as compared to normal hematopoietic cells).
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1. Introduction
Nanomedicine has gained much interest over the years because 
of its great potential to transport fragile, toxic, and poorly soluble 
drugs to the desired sites in the body. In the development of 
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/smll.201703774.
Small 2018, 1703774
www.advancedsciencenews.com www.small-journal.com
small
NANO MICRO
1703774 (2 of 10) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
for cancer therapeutics is rarely brought into contention due to 
the absence of alternative strategies. Recently, direct hydration, 
which utilizes oligo(ethylene glycol) (OEG) as a nontoxic dis-
persant, has been presented as an alternative strategy for the 
aqueous self-assembly of polymeric nanostructures.[28,29] Imple-
mentation of direct hydration in the fabrication of drug-loaded 
nanovectors could reduce dependence upon harmful solvents 
and provide a facile alternative to conventional methodolo-
gies. Given the ability of OEG to dissolve certain amphiphilic 
copolymers and facilitate their dispersion and self-assembly, 
we postulate that this approach would also be amenable to the 
generation of drug nanocarriers. However, the application of 
this alternative methodology toward drug encapsulation and its 
ability to produce well-defined composite nanovectors, at sizes 
under 100 nm, is not known. To this end we have explored the 
use of the biodegradable copolymer poly(ethylene glycol)-block-
poly(trimethylene carbonate) (PEG–PTMC) as a potential can-
didate for direct hydration. PTMC, which has established bio-
degradability,[30] and can be readily prepared using the nontoxic 
catalyst, methanesulfonic acid,[31,32] has been identified as an 
excellent candidate for drug delivery applications.[33,34] In this 
way, we can also use molecular design to engineer the struc-
tural features of copolymeric nanovectors, such as size, if the 
direct hydration process is amenable to such control.
The therapeutic context for this work is acute lymphoblastic 
leukemia (ALL), a challenging application that can directly ben-
efit from development of more efficacious treatments. ALL is 
the most common childhood cancer.[35–37] Survival rates, whilst 
markedly improved over the last 30 years, have started to pla-
teau and treatment-related toxicity has increased.[38] There has 
been little progress in the introduction of new agents over the 
past decade, largely due to the fact that hydrophobic drug can-
didates require dissolution in harmful organic solvents and 
attempts at chemical modification only tend to reduce thera-
peutic efficacy.[39,40] One such drug candidate, the sesquiterpene 
lactone parthenolide (PTL), has shown promising therapeutic 
efficacy against ALL with specificity against diseased cells over 
healthy blood cells.[40–43] PTL is a potent NF-κB inhibitor and, 
as such, has wide ranging implications in cancer therapy; how-
ever, poor aqueous solubility limits its utility.[44–47] For this 
reason, innovative strategies for the solubilization and delivery 
of hydrophobic (or sensitive) drug molecules are required 
to overcome the physical and biological barriers that hamper 
therapeutic performance.[48–53] Carrier-based approaches for the 
delivery of PTL have been applied to both lymphoblastic and 
myeloid leukemias.[54–56] Indeed, copolymer-based PTL delivery 
vectors have been reported to enhance drug bioavailability, 
showing therapeutic efficacy in vitro and also in vivo, however, 
the problem of carrier toxicity and producibility still remain.
Herein, we present direct hydration as a powerful tool to 
obtain drug-loaded PEG–PTMC nanovectors and their successful 
implementation in the development of a specific ALL thera-
peutic technology. Through careful optimization of the method-
ology, highly uniform PEG–PTMC micelles were prepared with 
a size dictated by their molecular composition (ranging from 
20–40 nm). Drug encapsulation, using parthenolide as a perti-
nent example, was accomplished by codissolution (up to 20 wt% 
w.r.t. copolymer) in OEG prior to hydration in buffer. Physical 
characterization, by means of multiple-angle light scattering 
(MALS) and nuclear Overhauser effect spectroscopy (NOESY) 
1H nuclear magnetic resonance (NMR), confirmed that this pro-
cess resulted in complete drug encapsulation (within the limits 
of detection) in discrete nanovectors that required no purifica-
tion or filtration (Figure 1). The resulting nanovectors show 
excellent nontoxicity toward primary cord blood (CB) cells and, 
after incorporation of 10 wt% PTL, showed unimpeded cytotox-
icity toward both T and B-cell precursor (BCP) ALL patient sam-
ples. In particular, it was apparent that the PTL nanovector was 
less cytotoxic toward CB cells, highlighting the potential of this 
formulation to actually increase therapeutic efficacy; not only 
provide a more robust and producible method of formation. 
We anticipate that the engineering of drug-loaded PEG–PTMC 
nanovectors, via direct hydration, constitutes a new platform 
technology for drug delivery that overcomes the problems of 
control, toxicity, and producibility.
2. Results
2.1. Evaluation of Copolymer Self-Assembly  
Using Direct Hydration
Block copolymers comprising varying lengths of PTMC with 
1 kDa PEG (Table S1, Supporting Information) were synthesized 
utilizing the nontoxic organocatalyst methanesulfonic acid 
according to literature protocols.[31,32] For simplicity, PEG–PTMC 
copolymers are denoted P30, P20, and P15 in relation to their 
PEG content of 30, 20, and 15 wt%, respectively. This process 
yielded well-defined copolymers with a polydispersity ≤ 1.1, 
Small 2018, 1703774
Figure 1. Schematic outlining the direct hydration methodology for the 
production of discrete nanovectors. Codissolution of PEG–PTMC copol-
ymer (chains colored blue and orange, respectively) and drug (red) in 
OEG (green solvent phase) is followed by stirring with aqueous buffer to 
create pristine nanovectors in under 10 min, without use of harmful sol-
vents. During direct hydration, as the two phases coalesce, copolymer and 
drug undergo rapid hydrophobic co-assembly into micellar constructs.
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which exist as viscous liquids or waxy solids at room temper-
ature. Self-assembly of PEG–PTMC copolymers was accom-
plished by dissolution at 50 wt% in viscous OEG (Mw = 350 Da, 
ρ = 1.09 g mL−1) and subsequent hydration through stir-
ring with buffer. No difference in size was observed between 
copolymer that was directly dissolved into buffer and those pre-
pared by direct hydration (Figure 2A). Nevertheless, it is impor-
tant to note that direct hydration is vital in the processing of 
neat (highly viscous/wax-like) PEG–PTMC copolymers due to 
the importance of drug-loading and ease of handling; which is 
impossible without OEG dissolution prior to assembly. Cryo-
genic transmission electron microscopy (cryo-TEM) images of 
P20 micelles confirmed the presence of spherical nanoscopic 
constructs, with low electron density (and thereby contrast) 
owing to their organic nature (Figure 2B). Dynamic light scat-
tering (DLS) yielded average hydrodynamic radii (Dh) of 23, 
28, and 30 nm for copolymers comprising P30, P20, and P15, 
respectively, all of which had narrow pdi values (<0.1) according 
to the Zetasizer software. In order to get a more accurate pic-
ture of the real size distribution of the micelles we utilized 
asymmetric flow field-flow fractionation (AF4) coupled with in 
line DLS (Table S2A, Supporting Information). AF4 is a flow-
based separation technique, which can provide unique insight 
into the structural characteristics of PEG–PTMC micelles, such 
as a linearly scaled size distribution and shape parameters. AF4 
measurements yielded micelle hydrodynamic diameters (Dh) 
of 18–22 (P30), 26–32 (P20), and 34–42 nm (P15) (Figure 2C). 
Analysis of the ratio between radius of gyration and hydro-
dynamic radius (Rg/Rh), or the particle shape ratio (ρ), was 
performed using AF4-coupled MALS. Although the smallest 
micelles were below the accepted limit of detection for Rg 
(<10 nm), ρ values of ≈0.8 were obtained for both P20 and P15 
micelles (Figure S3, Supporting Information), confirming their 
dense, spherical nature in accordance with the literature.[57] 
Zeta-potential measurement of P20 micelles were also per-
formed (in 20× diluted phosphate buffered saline (PBS)) and a 
value of −3 ± 0.5 mV was recorded.
2.2. Drug Loading and Nanovector Characterization
At this stage we selected the (intermediately sized) P20 micelles 
in order to evaluate drug loading and in vitro performance. 
From here on, references to micelle composition will refer to 
the wt% loading of drug (PTL) in P20 micellar particles rather 
than copolymer composition. Nanovector preparation through 
incorporation of PTL into the PEG–PTMC micelles was accom-
plished by codissolution of drug and copolymer in OEG, prior 
to hydration (Figure 1). Using this facile methodology we con-
firmed (using DLS) that the limit of encapsulation was in the 
region of 20 wt%, with aggregation or drug precipitation evident 
in a 25 wt% formulation (Figure S4, Supporting Information). 
Critical micelle concentrations (CMC) of apo and PTL nano-
vectors were measured using the fluorescent probe 8-anilinon-
aphthalene-1-sulfonic acid (ANS), which detects the presence of 
hydrophobic microenvironments through an increased fluores-
cent signal at 480 nm. Using the ANS method, CMC values of 
12 ± 0.5 and 10 ± 1.4 µg mL−1 (≈2 × 10−6 m) were measured for 
apo and 10 wt% PTL nanovectors, respectively (Figure 3A). In 
order to demonstrate the scalability of PTL solubilization using 
direct hydration, a homogenous nanovector dispersion was 
generated comprising 10 wt% PTL nanovectors up to a [PTL] = 
4 mg mL−1 (16.1 × 10−3 m), an increase of ≈100 fold as com-
pared to free drug (Figure 3B).
Figure 2. Formation of well-defined nanoparticles using direct hydration: A) Intensity size distribution plot for micelles comprising P15 (black), P20 
(red), and P30 (blue) prepared via direct hydration (P20 micelles were also prepared by stirring copolymer into buffer directly, red dashes), B) cryo-TEM 
image of P20 micelles, and C) AF4 data for copolymer micelles with sizes and distributions measured via in-line DLS.
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Due to the largely nonaromatic nature of PTL, which renders 
it chromatically invisible, alternative methodologies are required 
to evaluate nanovector composition. AF4-MALS/DLS was used to 
confirm that PTL loading did not have any effect upon the size 
distribution of the nanovectors; however, an increase in the molec-
ular weight of the particles was observed (Figure 3C). Having 
measured the refractive index increment (dn/dc) for PEG–PTMC 
as 0.1027 ± 0.0008 mL g−1 (Figure S5, Supporting Information), 
we obtained average values of 3.62 (± 0.1%) and 4.04 (± 0.3%) 
MDa for apo and PTL nanovectors, respectively. From these meas-
urements we can approximate the aggregation number (Nag) of 
the micelles as ≈739, which would mean that every chain would 
occupy in the region of 3 nm2 at the hydrated micelle periphery.
1H NMR measurements proved to be an excellent counter-
part to AF4-MALS for further interrogation of nanovector struc-
ture and PTL loading. In particular, 2D NOESY provides spatial 
information about the microenvironment of any given proton, 
which can be employed to identify the chemical composition 
of PTL nanovectors. NMR measurements were performed on 
10 wt% PTL-loaded nanovectors, which were directly hydrated 
into a D2O-based PBS buffer at a total [PTL] = 2.75 mg mL−1 
(11.1 × 10−3 m) and measured without any filtration or purifi-
cation. Cross peaks between PTL protons at 6.27, 5.82, and 
5.28 ppm and the core protons of PTMC at 4.16 and 1.99 ppm 
could only occur if there was long-lasting spatial interaction; 
indicating that PTL (which exists in a single environment as 
indicated by the singular nature of the proton resonances) was 
entirely sequestered in the PEG–PTMC micelles (Figure 3D). 
Some cross correlation between PTL and ethylene glycol pro-
tons was also evident in the 2D spectrum. Closer examination 
of the NMR data showed correlation between the core protons 
of PTMC and a broad (27 Hz) signal at 3.65 ppm, rather than 
the narrow (6 Hz) signal evident in the standard 1D NMR at 
3.67 ppm. This was due to correlation between PTMC and 
coronal PEG protons (broad signal at 3.65 ppm), as opposed 
to those of OEG (sharp signal at 3.65 ppm) that was free in 
solution and not present within the micelles (Figure S6, Sup-
porting Information). Indeed, the correlation of PTL in the 
2D NMR was with the broad coronal PEG at 3.65 ppm, which 
can occur due to drug at the core/coronal interface or via a relay 
signal from the PTMC protons. In addition to NOESY meas-
urements, the T1 and T2 relaxation parameters were measured 
and the results correlated with previous observations. Compar-
ison between the values of free drug protons and loaded drug 
protons supports the complete encapsulation of PTL. T1 and T2 
values of protons A and B of PTL decreased by around 50% and 
95%, respectively (Table S3, Supporting Information). Lower 
relaxation times clearly indicate that PTL tumbles more slowly 
in the nanovector formulation, due to its sequestration inside 
the dense micelle core.
2.3. Stability and Drug Release Characteristics  
of PTL Nanovectors
To further characterize the physical properties of the nanovector 
formulation we conducted experiments to determine particle 
stability, PTL release profile and copolymer stability in PBS 
and human serum (HS). Standard dosimetry in vivo requires 
multiple doses of PTL due to its short half-life (in the order of 
hours),[58] which means that particle stability should be evaluated 
over hours and days. Consistent correlation DLS data of unfil-
tered samples showed that particles were stable over the course 
of 6 d in PBS at 37 °C (Figure S7, Supporting Information), 
which was supported by AF4 (Figure S8, Supporting Informa-
tion). To confirm particle stability in HS, however, DLS could not 
be used due to high turbidity. To demonstrate stable drug encap-
sulation in HS, we engineered Förster (fluorescence) resonance 
energy transfer (FRET) micelles using the lipophilic fluorescent 
tracers 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO) and 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlo-
rate (DiI). DiO/DiI FRET pairing was tailored in the PEG–PTMC 
system, using direct hydration, to provide a fluorescent read-out 
that confirms the integrity of discrete nanovectors in complex 
media, a strategy employed in similar systems.[59] Indeed, FRET 
micelles hydrated into PBS or HS demonstrated equivalent 
Small 2018, 1703774
Figure 3. PTL nanovector characterization: A) Critical micelle concentration (CMC) determination of apo- (blue) and PTL (red) P20 nanovectors via 
ANS fluorescence, B) images demonstrating the stability of the nanovector formulation at elevated [PTL] as compared to free PTL in solution that 
undergoes (visible) aggregation, C) AF4-MALS data showing the normalized differential refractive index signals (near-Gaussian traces) and contrasting 
the hydrodynamic diameter (dots) and molecular weight values (solid lines) of apo- (blue) and PTL (red) nanovectors, and D) 2D NMR NOESY data 
for 10 wt% PTL nanovectors, showing strong spatial correlations between PTL protons (upper) and those of PEG–PTMC (left).
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stability with strong FRET signals from DiI at 570 nm, which is of 
critical importance to the performance of such a system in vitro 
and in vivo (Figure 4A). In addition, both AF4 measurements, 
gel permeation chromatography (GPC), and 1H NMR were per-
formed on samples that were incubated in HS at 37 °C. Neither 
the copolymer molecular weight (monitored by GPC retention 
time and peak width) nor the composition (extracted from the 
NMR spectra) showed any noticeable change over the course of 
6 d (Figure S9, Supporting Information). AF4 also demonstrated 
the stability of nanovectors in HS after 6 d, with a single pop-
ulation of micelles clearly visible once the serum proteins had 
been washed away (Figure 4B; Table S2B, Supporting Informa-
tion). Even after 3 weeks, a discrete population of nanovectors 
was still visible in samples prepared in PBS and HS, with only 
a slight increase (1–2 nm) in the Rh observed during that time 
(Figure S10, Supporting Information).
The pharmacokinetics of PTL release from nanovectors is 
an important determinant in their therapeutic performance. 
Under conditions of dilution similar to those used for in vitro 
studies (2 mL of PTL nanovector at [PTL] = 0.5 mg mL−1, 
2 × 10−3 m, suspended in 0.6 L buffer), we monitored the [PTL] 
inside the dialysis bag, and thereby inside the nanovector, by 
1H NMR (Figure S11, Supporting Information). For both PBS 
and HS samples, first order drug release was observed ([PTL] = 
[PTL]0.e−Kt) where K = 0.73 ± 0.08 and 0.59 ± 0.04 h−1, respec-
tively (Figure 4C). Drug release half times, t1/2 ( = 0.639/K) were 
calculated to be 0.9 ± 0.1 and 1.1 ± 0.1 h for samples in PBS 
and HS with 90% release being reached after 4–5 h. At double 
the concentration of nanovectors, and less dilute conditions 
(30 as compared to 300-fold), the release kinetics of PTL were 
slowed, with K = 0.2 ± 0.1 (t1/2 ≈ 4 h) and only ≈65% release 
being reached after 5 h (Figure S12, Supporting Information).
2.4. Performance of PTL Nanovector Against ALL In Vitro
In vitro studies were performed using T- and B-cell precursor 
ALL patient cells, the latter of which account for the majority 
of pediatric ALL cases diagnosed (with T-ALL accounting for 
≈15%). CB was used as a normal control and all the patient 
characteristics are summarized in Table S4 in the Supporting 
Information. In this work two parameters were varied: 
(1) the loading of PTL in nanovectors and (2) the overall [PTL] 
in solution. To ascertain IC50 values we systematically increased 
[PTL]total to assess cytotoxicity; however, when comparing nano-
vectors of different drug loadings the overall [copolymer] varied 
(e.g., at any given [PTL]total, a 10 wt% nanovector solution 
contains twice the amount of copolymer, and thereby micelles, 
as in the 20 wt% nanovector). The performance of PTL nano-
vectors was compared to free drug, which was added as a 
dimethylsulfoxide (DMSO) solution to the cells. Although the 
usage of free PTL can be regarded as a positive control, the 
necessity to dissolve the compound in organic solvent prevents 
its use in in vivo application. We therefore wanted to find the 
optimal nanovector system that performed as well as free PTL, 
but then at physiologically relevant conditions.
Initially, we compared the effect of PTL loading using PEG–
PTMC nanovectors comprising 10 or 20 wt% PTL in single 
samples. BCP and T-ALL samples for this comparison were 
selected based on known high PTL resistance, as any increase 
in cytotoxicity based on PTL loading could be more easily noted. 
In each sample, using 10 wt% PTL loading, a small increase 
in cytotoxicity was observed compared to 20 wt% loading; with 
IC50 values of 12.28 and 13.67 × 10−6 m (CB cells), 9.97 and 
11.91 × 10−6 m (BCP-ALL, pt. 5), and 9.10 and 11.10 × 10−6 m 
(T-ALL, pt. 2) (Figure 5A). To further evaluate the effect of PTL 
loading, 2.5, 5, and 10 wt% nanovectors were fabricated and 
tested against four T-ALL samples, which comprised the PTL 
resistant (pt. 2) sample and three additional samples that were 
highly sensitive to PTL. In all four samples, no significant dif-
ferences in toxicity were observed between formulations, with 
average IC50 values of 3.82, 3.57, and 3.60 × 10−6 m measured 
for 2.5, 5, and 10 wt% PTL nanovectors, respectively (P ≥ 0.94, 
Figure S13, Supporting Information). The higher sensitivity of 
the additional three T-ALL samples accounts for the drop in 
IC50 compared to the 10 wt% nanovectors in pt.2 (9.10 × 10−6 m) 
to the average in all four samples (3.60 × 10−6 m). All PTL nano-
vector formulations were equally as effective and showed no 
Figure 4. Nanovector stability and release characteristics: A) Schematic for the generation of FRET micelles and the fluorescence data showing the 
normal behavior of DiO (green) or DiI (red) micelles and of FRET micelles hydrated in PBS (dotted line) or HS (solid black line), B) AF4-DLS data for 
nanovectors after 6 d of incubation in serum at 37 °C with normalized signals for sample absorbance at 280 nm (solid line) and the scattering intensity 
(dotted line) plotted along with the hydrodynamic diameter (dots), and C) PTL release characteristics of nanovectors in PBS (blue) and serum (red) 
with the normalized [PTL] (solid symbols and lines) and percentage release data (hollow symbols and dashed line) plotted.
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significant differences to the toxicity of free PTL dissolved in 
organic solvent (IC50 of 3.59 × 10−6 m, P ≥ 0.94). Significantly, 
apo-nanovectors had no toxic effects on these samples, even 
at the highest micelle concentrations of 0.1 mg mL−1. Conse-
quently, PTL was used at loading weights ≤10 wt% for all sub-
sequent experiments.
Side-by-side evaluation of 10 wt% PTL nanovectors showed 
that cytotoxicity was not significantly different between T-ALL 
and BCP-ALL (P ≥ 0.8) across all doses and was significantly 
reduced toward CB cells (Figure 5B–D; Figure S14, Supporting 
Information). As already stated, 10 wt% PTL nanovector 
treatment in the four T-ALL samples gave an average IC50 of 
3.60 × 10−6 m (P = 0.01). For the three BCP-ALL samples 
tested, an average IC50 of 4.38 × 10−6 m PTL (P = 0.02) was 
obtained with the efficacy of the PTL nanovector being similar 
to that of free PTL, which had an IC50 of 3.76 × 10−6 m  
(P = 0.79). Again, no toxicity was observed of the apo-nano-
vector at all concentrations. Concerning CB, treatment with 
10 wt% PTL nanovectors showed significantly lower toxicity 
(IC50 12.45 × 10−6 m PTL) as compared to the effects on 
BCP-ALL (P = 0.02) or T-ALL (P = 0.03) cells. Although the 
effects of PTL nanovectors on CB cells were similar to that of 
free PTL (IC50 10.37 × 10−6 m) up to 5 µm, at 10 × 10−6 m free 
PTL was significantly more toxic to these cells (P = 0.01). Once 
again, no toxicity was observed using the apo-nanovector. 
Apo-nanovector toxicity was also assessed at higher concen-
trations in CB cells, only at a concentration of 5 mg mL−1 
PEG–PTMC was a small drop in viability observed (90 ± 15%, 
Figure S15, Supporting Information).
In order to explore the biochemical mechanism of PTL 
nano vector activity we explored the induction of reactive oxygen 
species (ROS) stress and inhibition of NF-κB in leukemia 
cell apoptosis. In all four T-ALL samples, preloaded with the 
ROS sensitive probe CM-H2DCFDA, ROS levels significantly 
increased when treated with 2.5 (11.76 ± 3.32 fold), 
5 (12.32 ± 1.69 fold), or 10 wt% (11.66 ± 1.66 fold) PTL nano-
vectors and free PTL (13.23 ± 2.88 fold) compared to untreated 
cells (P ≤ 0.03). No significant difference in ROS levels was 
observed between the cells treated with the various PTL 
formulations (P ≥ 0.99) and, as expected, apo-nanovectors 
showed no significant ROS inducing effects on these sam-
ples. (Figure 6A). Phosphorylation of the NF-κB subunit, p65, 
is an indicator of NF-κB activation, which PTL is known to 
inhibit. Indeed, phosphorylated p65 expression was signifi-
cantly reduced in cells treated with either PTL nanovectors 
(13.85 ± 8.01 au, P ≤ 0.0001) or free PTL (13.10 ± 8.61 au, 
P ≤ 0.0001) compared to cells treated with unloaded nano-
vectors (31.76 ± 15.08 au) (Figure 6B).
Having demonstrated that PTL is functionally indistinct 
against ALL cells in vitro when formulated within PEG–PTMC 
micelles, we assessed the delivery of hydrophobic cargo via the 
extracellular membrane using a model fluorescent dye. Using 
fluorescent nanovectors, loaded with 1 wt% DiO, cell uptake 
could be assessed. T-ALL samples treated with DiO nanovectors 
at 37 °C showed a mean increase of 1.58 ± 0.16 fold in DiO flu-
orescence after 30 min of treatment increasing to a maximum 
of 2.91 ± 0.18 fold increase after 24 h (Figure S16, Supporting 
Information). Incubating cells with DiO nanovectors at lower 
temperatures significantly reduced cellular fluorescence, with a 
1.05 ± 0.02 (P ≤ 0.0001) fold increase at 4 °C and 0.98 ± 0.08 
(P ≤ 0.0001) at 22 °C after 3 h, compared to 2.29 ± 0.07 at 
37 °C after the same time interval. To directly assess if nano-
vectors were up-taken via endocytosis in T-ALL cells, Dynasore 
(a dynamin inhibitor) was applied to samples prior to 
incubation. Dynamin inhibition resulted in lower fluorescence 
uptake in cells at all time points analyzed, with a 1.2 ± 0.05 fold 
increase (P ≤ 0.0001) in dynamin inhibited cells after 3 h com-
pared to 2.0 ± 0.05 in uninhibited cells. (Figure 6C).
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Figure 5. In vitro efficacy of PTL Nanovectors against ALL: A) Comparison of cytotoxicity caused by 10 (dotted lines) or 20 (solid lines) wt% PTL 
nanovectors in a T-ALL, BCP-ALL, and cord blood sample. B–D) Comparison of 10 wt% PTL nanovector (blue line) cytotoxicity versus unloaded 
nanovector (black line) and free PTL (red line) in primary samples from T-ALL (n = 4), BCP-ALL (n = 3), and cord blood (n = 3). Data represent mean 
± SD. Results were analyzed by a two-way ANOVA.
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3. Discussion
The utility of direct hydration for the self-assembly of PEG–
PTMC copolymers was exemplified by the size control (deter-
mined by copolymer composition) and strikingly narrow 
distributions of the resulting spherical micelles (Figure 2; 
Figure S3, Supporting Information). These results exempli-
fied the chemical compatibility between OEG and PEG–PTMC, 
which was sufficiently versatile to facilitate drug (PTL) incorpo-
ration in a robust process. Indeed, PTMC was chosen for this 
research based on observed affinity for direct hydration and 
its favorable assembly behavior, tending toward the formation 
of spherical micelles. The ability to codissolve copolymer and 
drug in OEG and hydrate such well-defined, structurally dis-
crete nanoparticles (reminiscent of the structural uniformity of 
viruses), in a process that takes less than 10 min, makes this a 
valuable technological platform.
Evaluation of the physicochemical properties of PTL nano-
vectors, comprising copolymer P20, yielded maximal drug 
loadings in the region of 20 wt% (Figure S4, Supporting Infor-
mation) and CMC values in the low-micromolar regime; at 
least 100-fold lower than commercial surfactants and amphi-
philic copolymers (Figure 3A). By upscaling the formula-
tion to [PTL] = 4 mg mL−1 (10 wt% w.r.t. copolymer) we suc-
cessfully obtained nanovectors without evidence of aggregation 
(Figure 3B). Thereafter, we wanted to understand if, indeed, 
the nanovector formulation was as nanoscopically uniform as 
initial analysis indicated. To that end, 1H NOESY NMR and 
AF4-MALS provided the detailed structural insights necessary. 
Molecular weight determination, using AF4-MALS, confirmed a 
mass increase of ≈10 wt% and no significant change in micelle 
size as a result of PTL loading (at 10 wt%, Figure 3C; Figure S5, 
Supporting Information). To corroborate this, (1H) 2D NOESY 
and relaxation time measurements confirmed that (within the 
detection limits) all drug present in solution was strongly asso-
ciated with the micelle core (Figure 3D; Table S3, Supporting 
Information). Moreover, the role of OEG, as a dispersant that 
does not interact with the resulting nanostructures was also 
confirmed (Figure S6, Supporting Information). Therefore, we 
not only present a robust methodology but have demonstrated 
that the resulting drug nanovectors are, on a nanoscopic level, 
homogenous and not requiring purification.
As a biodegradable copolymer, PEG–PTMC is known to 
breakdown under physiological conditions;[60] however, it is not 
well known how this can affect nanoparticles. We observed that 
PTL nanovectors did not undergo disassembly over the course 
of 6 d in PBS or HS, as detected by DLS (Figure S7, Supporting 
Information), FRET measurements (Figure 4A), AF4-DLS 
(Figure 4B; Figure S8, Supporting Information) or by moni-
toring copolymer chain integrity (Figure S9, Supporting Infor-
mation). Extending stability measurements to 3 weeks high-
lighted the stability of the nanovector platform in both PBS and 
HS (Figure S10, Supporting Information). An observed increase 
in the hydrodynamic size of nanovector in HS was likely due to 
protein adsorption. Interestingly, the utility of AF4 was show-
cased by the separation from serum proteins from pristine nano-
vectors in order to directly observe their presence after direct 
hydration into HS. First order release of PTL (in PBS or HS) 
from the nanovectors, under dilute dialysis conditions, high-
lighted the discrete nature of the formulation; where the absence 
Figure 6. Evaluation of PTL nanovector function in vitro: A) Comparison of ROS induction in T-ALL samples by PTL loaded nanovectors (2.5%, 5%, 
and 10%), free PTL, and unloaded nanovector at a dose of 10 × 10−6 m for 1 h (data expressed as fold change from untreated cells). B) Representative 
fluorescence image showing the expression of phosphorylated p65 (green fluorescence) in T-ALL cells treated with 10 wt% PTL nanovectors, unloaded 
nanovectors, or unmodified PTL for 4 h. Expression was quantified in ImageJ in 50 cells from each treatment group. C) Comparison of the uptake 
of 1 wt% DiO nanovectors in T-ALL samples with or without endocytosis inhibition by Dynasore or under different temperatures during incubation 
(4, 22, or 37 °C). Data expressed as fold change in DIO fluorescence from unloaded nanovectors. Data represent mean ± SD. Results were analyzed 
by one-way ANOVA.
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of a “burst” release indicated a gradual diffusion of uniformly 
encapsulated cargo (Figure 4C; Figure S11, Supporting Infor-
mation). Release of 80–90% of drug within 5 h (to an overall 
[PTL] well below the solubility limit) was not surprising as PTL 
is known to release more rapidly in contrast to more hydro-
phobic molecules, such as Nile Red or DiO.[61] Repeating release 
studies under conditions closer to those that would be used in 
vivo (higher [nanovector] and less dilution), a dramatic reduc-
tion in release kinetics was observed, with a fourfold increase in 
t1/2 (Figure S12, Supporting Information). This highlights that 
the release of PTL from nanovector occurs as a consequence of 
PTL diffusion, dictated by the local environment.
In order to demonstrate that this platform technology can 
be applied to cancer therapy, we have evaluated the efficacy of 
PTL nanovectors toward ALL. This biodegradable nanovector 
platform was justified by the exquisite nontoxicity of the apo-
nanovector toward sensitive patient cell samples; a challenge 
in developing ALL nanotherapeutics (Figure S14, Supporting 
Information).[54,55] Using up to [PEG–PTMC] = 5 mg mL−1 
no toxicity toward CB cells was observed, demonstrating 
that biodegradable nanovectors were, indeed, biocompatible 
(Figure S15, Supporting Information). In vitro assays exam-
ining the effect of drug loading, indicated that 2.5–10 wt% PTL 
nanovectors were equally as effective, with a slight reduction 
in cytotoxicity at higher loading, contrary to popular thought 
(Figure 5A; Figure S13, Supporting Information). A key feature 
of PTL is its reported specificity toward ALL and limited effect 
upon healthy hematopoietic cells.[40,43] Indeed, this behavior 
was translated to the PTL nanovector platform, which showed 
excellent cytotoxicity toward a range of T- and BCP-ALL patient 
samples (Figure 5B,C). Interestingly, we observed that PTL 
nano vectors were significantly less toxic toward healthy CB 
cells at 10 × 10−6 m PTL (Figure 5D), which points toward spe-
cific therapeutic advantages for this system.
To further evaluate PTL nanovector performance, in vitro, we 
performed a number of biochemical assays associated with PTL 
activity; monitoring ROS levels, NF-κB expression, and nano-
vector uptake.[43,62] In agreement with cytotoxicity studies, PTL 
nanovectors induce ROS and inhibit NF-κB in a similar fashion 
to free PTL, as opposed to other untargeted systems that can 
inhibit drug activity (Figure 6A,B). Using an endocytotic 
inhibitor (Dynasore) we also examined cellular uptake of nano-
vectors.[63] DiO-loaded nanovectors were taken up by T-ALL 
cells most strongly over the first few hours; however, this 
continued over the following 24 h (Figure S16, Supporting 
Information). Nanovector uptake was interrupted both by the 
cessation of endocytosis or by incubation of cells at lower tem-
peratures, confirming that particle uptake is occurring during 
the same timescales as in vitro studies (Figure 6C).
4. Conclusion
In this work, we have presented a novel methodology for the 
preparation of biodegradable, drug loaded nanovectors and 
established their utility in the treatment of ALL in vitro. Direct 
hydration provides a uniquely facile method for the preparation 
of well-defined, drug-loaded nanovectors that can be prepared 
with physical features (such as size) dictated by their chemical 
composition. Moreover, such nanovectors possess complete 
drug encapsulation that justifies direct implementation without 
purification or postprocessing. Parthenolide, a potent NF-κB 
inhibitor that has wide-ranging applications in cancer therapy, 
was effectively incorporated in PEG–PTMC nanovectors and, 
thereafter, effectively applied toward in vitro studies using 
ALL patient samples. With excellent biocompatibility of the 
apo-nanovector and specific cytotoxicity of PTL-loaded nano-
vectors, the potential of this system is clearly demonstrated. 
We anticipate that this platform can readily be applied to a 
wide range of drugs and to engineering more complex copoly-
meric nanosystems for application in cancer therapy; free from 
the constraints of complex fabrication processes, background 
toxicity or impeded drug efficacy.
5. Experimental Section
Materials: All chemicals were used as received unless otherwise stated. 
For the synthesis of the block copolymers, monomethoxy mPEG22-OH 
(1 kDa) was purchased from Rapp Polymers and trimethylene carbonate 
from Acros Organics. For in vitro analysis of cells; l-glutamine, penicillin/
streptomycin, fetal calf serum, ROS probe CM-H2DCFDA, and Hanks 
balanced salt solution (HBSS) were supplied by Thermo Scientific. 
Annexin-V-FITC and propidium iodide (PI) were supplied by Miltenyi 
Biotec. All other chemicals were supplied by Sigma-Aldrich. Ultra-pure 
MilliQ water obtained from a Labconco Water Pro PS purification system 
(18.2 MΩ) was used for the phosphate buffer solutions. Details of all 
instrumentation used for particle characterization can be found in the 
Supporting Information. Paediatric leukemia and normal cord blood 
samples were obtained with written consent and with approval of 
University Hospitals Bristol NHS Trust and the National Research Ethics 
Committee London-Brent.
Organocatalyzed Synthesis of PEG–PTMC Block Copolymers: Using a 
modified literature procedure,[31] monomethoxy PEG-OH (Mw = 1 kDa, 
Đ < 1.1) was weighed into a dried round bottom flask (typically 0.1 mmol, 
105 mg), to which a stoichiometric amount of trimethylene carbonate 
was added (either 5.2, 3.8, or 2.2 mmol for copolymers comprising 15, 
20, or 30 wt% PEG, respectively). Dry toluene (≈50 mL) was then added 
and evaporated, in order to ensure dryness prior to polymerization. Dried 
reagents were then dissolved in dry dichloromethane (DCM, 10 mL) 
and methanesulfonic acid (0.1 mmol = 6.2 µL) was added under argon 
to initiate polymerization. The reaction was stirred at 30 °C for 24 h, 
until no monomer was observed in the 1H NMR spectrum (Figure S1, 
Supporting Information). The reaction mixture was subsequently diluted 
with DCM and washed with saturated NaHCO3 then brine before drying 
over Na2SO4, concentrated and precipitated into ice cold diethyl ether 
(≈100 mL). After decanting excess ether, the waxy solid was redissolved 
in dioxane and lyophilized for ease of storage and handling. Yields of 
80–90% were obtained with the exact composition determined by 
1H NMR (Figure S2, Supporting Information) and polydispersity determined 
by gel permeation chromatography (Table S1, Supporting Information).
Micelle Formation and Drug Encapsulation via Direct Hydration: PEG–
PTMC was dissolved in OEG at 50 wt% at 45 °C with manual mixing to 
ensure homogeneity. Subsequently, 10 µL of this viscous solution was 
added to the bottom of a 5 mL vial and stirred at 200 rpm with buffer 
then added up to the desired [copolymer] and left to hydrate for 10 min. 
Drug encapsulation was accomplished by codissolution of PTL powder 
into the initial OEG solution at the desired ratio to copolymer without 
the need for purification. Drug loading was determined with 1H NMR 
NOESY and relaxation experiments. Technical details can be found in 
the Supporting Information.
CMC Determination: CMC values for P20 micelles (with and without 
10 wt% of PTL) were determined using ANS (λex = 360 nm/λem = 
480 nm). A dilution series was made of the micellar solutions in 
a multiwell plate (190 µL in each well) and 10 µL of 1 × 10−3 m ANS 
Small 2018, 1703774
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was added to each. Measurements were performed at 37 °C and the 
fluorescence intensity at 480 nm was used as a read-out.
Nanovector Stability and Drug Release Studies: Nanovector stability in 
both PBS and HS was monitored using DLS, GPC, and AF4 (see the 
Supporting Information for technical details). In order to monitor drug 
release and copolymer (P20) stability, 2 mL of 10 wt% PTL nanovector 
solutions were suspended at a [copolymer] = 5 mg mL−1 (with [PTL] = 
2.2 × 10−3 m) in a dialysis bag (MWCO 3.5 kDa) within 600 mL of PBS 
at room temperature. Under conditions of increased concentration, and 
less dilution, nanovectors at [copolymer] = 10 mg mL−1 (with [PTL] = 
1 mg mL−1, 4 × 10−3 m) were prepared and 8 mL was dialyzed against 
250 mL of PBS at room temperature. The nanovector solution was 
lyophilized at sequential time points, redissolved in CDCl3 and filtered 
(0.2 µm PTFE) before measurement by GPC and NMR. To determine 
PTL content from the 1H NMR spectra, PTL peaks at 6.3 and 5.6 ppm 
were normalized against the PTMC peak at 4.2 ppm.
Formation of FRET micelles, to demonstrate stability in human 
serum, was accomplished using a slight modification to the 
aforementioned method. Coencapsulation of DiO and DiI was achieved 
by first dissolving both components in OEG. Thereafter, PEG–PTMC 
was dissolved into this dye/OEG solution up to [copolymer] = 50 wt% 
and FRET micelles were prepared via direct hydration (as previously 
described). Optimal loading of DiO and DiI, where maximal FRET was 
observed by UV–vis, was found to be 0.06 and 0.247 wt%, respectively.
PTL Nanovector Cytotoxicity Inducing Cell Death: For cytotoxicity 
testing, cells were plated at 2 × 105 per mL in RPMI-1640 supplemented 
medium and treated with PTL nanovectors or free PTL (1–10 × 10−6 m). 
Cells were then incubated with drug for 24 h (37 °C, 5% O2, 5% CO2). 
After incubation, the cells were washed and resuspended in HBSS 
containing Annexin-V conjugated to FITC for 10 min at 4 °C in the dark. 
Cells were then washed, resuspended in HBSS, and stained with PI 
(1 µg mL−1) immediately prior to flow cytometric analysis.
ROS Induction and Inhibition of NF-κB by PTL Nanovectors: To test ROS 
induction, T-ALL cells from four pediatric patients were plated at 2 × 105 
cells per mL in HBSS containing 2% human serum albumin. Cells were 
treated with 5 × 10−6 m of the redox sensitive probe 5-(6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) for 30 min at 37 °C. 
Cells were washed and incubated for 1 h with PTL nanovectors (2.5%, 
5%, or 10% PTL loading), free PTL (in both cases [PTL]total = 10 × 10−6 m) 
or apo-nanovector. After treatment cells were washed, resuspended in 
HBSS, and stained with PI to exclude dead cells immediately prior to flow 
cytometric analysis. For phosphorylated p65 staining, 5 × 104 cells from 
patient sample 4 were treated with 10 × 10−6 m PTL (10 wt% PTL loading 
in nanovectors or free PTL) or unloaded nanovectors for 4 h. During PTL 
incubation cells were left to settle onto poly-d-lysine coated coverslips. 
Cells were washed three times in PBS and fixed in 2% paraformaldehyde 
for 10 min at 4 °C. Cells were washed three times in PBS and treated with 
staining buffer containing 3% fetal bovine serum (FBS) and 0.1% triton 
x-100 in PBS for 1 h. Cells were then treated with either rabbit antihuman 
phospho p65 (pp65, 1:100) or rabbit IgG control (1:100) antibody in 
staining buffer for 16 h at 4 °C. Cells were washed three times in PBS and 
treated with goat antirabbit IgG conjugated to alexa fluor 488 (1:100) in 
staining buffer for 1 h at room temperature (RT) in the dark. Cells were 
washed three times in PBS and mounted onto slides with prolong gold 
mounting medium containing DAPI. Cells were imaged on a Leica SP8 
AOBS confocal laser scanning microscope.
Cellular Uptake of Fluorescent (DiO) Nanovector: To measure 
nanovector uptake, PEG–PTMC micelles were loaded with 1 wt% DiO 
in a similar fashion to the DiO/DiI FRET micelles. To assess uptake 
in T-ALL samples, cells were plated at 2 × 105 per mL in RPMI-1640 
supplemented medium and treated with nanovectors for up to 24 h. 
To assess if uptake was blocked by temperature changes, cells were 
incubated at 37, 22, or 4 °C for 30 min prior to and during nanovector 
incubation. To assess if uptake was blocked by inhibiting endocytosis 
via dynamin inhibition, cells were incubated with 80 × 10−6 m dynasore 
hydrate for 30 min prior to and during nanovector incubation at 37 °C. 
After incubation cells were washed and resuspended in HBSS and 
stained with PI immediately prior to flow cytometric analysis.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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